[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 12, 2006, Pages 1387-1398

  Cimitan, Marino ^a   Bortolus, Roberto ^a   Morassut, Sandro ^a   Canzonieri, Vincenzo ^a   Garbeglio, Antonio ^b   Baresic, Tanja ^a   Borsatti, Eugenio ^a   Drigo, Annalisa ^a   Trovò, Mauro G ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b S Maria Degli Angeli Regional Hospital   (Italy)

Author keywords

Choline; PET; Prostate cancer

Indexed keywords

FLUORINE 18; FLUOROCHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROCHOLINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; BLOOD; CELL DIFFERENTIATION; CELL PROLIFERATION; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TIME;

AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845357517     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0150-2     Document Type: Article

References (40)

1. Buchanan G, Irvine RA, Coetzee GA, Tilley WD. Contribution of the androgen receptor to prostate cancer predisposition and progression. Cancer Metastasis Rev 2001;20:207-223
2. Loblaw A, Mendelson D, Talcott J, Virgo K, Somerfield M, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927-2941
3. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma. Early versus late endocrine therapy. Urol Clin North Am 1991;18:15-24
4. Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A sub analysis of EORTC trial 30853. The EORTC Urological Group. Cancer 1990;66:1009-1016
5. Parivar F, Hricak H, Shinohara K, Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996;48:594-599
6. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59-85
7. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115-138
8. Nudell DM, Wefer AE, Hricak H, Caroll PR. Imaging for recurrent prostate cancer. Radiol Clin North Am 2000;38:213-229
9. May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66-69
10. Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, et al. Advances in imaging in the postoperative patients with a rising prostate-specific antigen level. Semin Oncol 2003;30:616-634
11. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Group. J Urol 1998;159:2041-2046
12. Cher M, Bianco F Jr, Lam J, Davis L, Grignon D, Sakr W, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998;160:1387-1391
13. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632-1642
14. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001;76:576-581
15. Dotan Z, Bianco F, Rabbani F, Easthman J, Fearn P, Scher H, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962-1968
16. Hoh CK, Seltzer MA, Franklin J, deKernion JB, Phelps ME, Belldegrum A. Positron emission tomography in urological oncology. J Urol 1998;159:347-356
17. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-35
18. Liu IJ, Zafar MB, Lai YH, Segall GM, Terri MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-111
19. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-995
20. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinshmidt K, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27;1415-1419
21. 11C-choline positron emission tomography. Eur Urol 2002;42:18-23
22. Coleman R, De Grado T, Wang S, Baldwin S, Orr M, Reiman R, et al. Preliminary evaluation of F-18 Fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147
23. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-555
24. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001;61:110-117
25. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34:274-292
26. 11C-acetate whole-body PET. J Nucl Med 2004;45:1233-1236
27. 18F-fluorocholine. J Nucl Med 2002;43:92-96
28. Schmid D, John H, Zweifel R, Cservenyak T, Westera G, Goerres G, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005;235:623-628
29. 18F] fluorodeoxyglucose-positron emission tomography. J Urol 2003;169:1337-1340
30. 11C-choline PET. J Nucl Med 2003;44:331-335
31. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44:32-39
32. 11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2004;31:317-324
33. 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging 2005;32:742-748
34. 11C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-1649
35. Hara T, Yuasa M. Automated synthesis of fluorine-18 labeled choline analogue: 2-fluoroethyl-dimethyl-2oxyethylammonium [abstract]. J Nucl Med 1997;38(suppl):44P
36. 18F- fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002;43:187-199
37. 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001;42:1805-1814
38. 18F] fluorodeoxyglucose for positron tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-280
39. 18F-fluorocholine PET. J Nucl Med 2006;47:262-269
40. Freedland S, Sutter M, Dorey F, Aronson W. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy: prostate-specific antigen. Urology 2003;61:365-369